Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Lawrence Brack

Ophthalmology Lithonia, GA Medical Doctor

NPI 1265441315 CMS profile 328893

5900 Hillandale Dr, Suite 345, Lithonia, GA 30058

Open in the dashboard

General payments

$421

14 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Lawrence Brack of Lithonia, GA is reported in the CMS Open Payments database as having received $421 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 29th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $12 1
2023 General $79 4
2022 General $102 2
2021 General $91 2
2020 General $99 3
2019 General $38 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Brack
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Lawrence Brack were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Lawrence Brack Ophthalmology median Middle half National median
2019 $38 $258 $104–$655 $163
2020 $99 $126 $45–$321 $114
2021 $91 $205 $76–$534 $132
2022 $102 $266 $100–$678 $149
2023 $79 $308 $117–$745 $160
2024 $12 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alcon Vision LLC $104 5 payments
  2. Allergan Inc. $80 2 payments
  3. Johnson & Johnson Surgical Vision, Inc. $73 1 payment
  4. Horizon Therapeutics plc $70 1 payment
  5. Glaukos Corporation $43 2 payments
  6. Bausch & Lomb, a division of Bausch Health US, LLC $20 1 payment
  7. Carl Zeiss Meditec AG $19 1 payment
  8. New World Medical,Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $322 11 payments
  2. Education $80 2 payments
  3. Gift $19 1 payment
Products named General payments · program years 2019–2024
  1. Clareon $86 4 payments
  2. DURYSTA $80 2 payments
  3. Tecnis IOL $73 1 payment
  4. TEPEZZA $70 1 payment
  5. iStent inject W $21 1 payment
  6. ENVISTA $20 1 payment
  7. None Specified $19 1 payment
  8. Centurion $18 1 payment
  9. Kahook Dual Blade $12 1 payment
  10. Clearpath $12 1 payment
  11. Other $23 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

2,881

Median for Ophthalmology: 891

Drug cost

$285,977

Median for Ophthalmology: $68,233

Branded share of claims

19.6%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 127 $95,296
Xiidra Lifitegrast Brand 81 $78,441
Cyclosporine Generic 38 $17,493
Prednisolone Acetate Generic 388 $17,313
Lumigan Bimatoprost Brand 31 $17,161
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 42 $9,442
Combigan Brimonidine Tartrate/Timolol Brand 19 $8,688
Latanoprost Generic 800 $7,212
Timolol Maleate Generic 115 $5,407
Ofloxacin Generic 321 $5,376

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$106,180

Medicare's payments for the services billed

Medicare patients

525

Average age 74

Services billed

1,287

307 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 47%
Chronic kidney disease 37%
Ischemic heart disease 30%
Atrial fibrillation 21%
Heart failure 19%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record